Figures & data
Figure 1. —Patient disposition. ICS, inhaled corticosteroid; FP/S, fluticasone propionate/salmeterol combination; MF/F, mometasone furoate/formoterol. *Patient population used for safety analyses. †Patient population used for efficacy analyses, identified before database lock.
![Figure 1. —Patient disposition. ICS, inhaled corticosteroid; FP/S, fluticasone propionate/salmeterol combination; MF/F, mometasone furoate/formoterol. *Patient population used for safety analyses. †Patient population used for efficacy analyses, identified before database lock.](/cms/asset/44634857-f48c-41cb-832e-e6bb51e9f4d8/ijas_a_514634_f0001_b.gif)
Table 1. —Patient demographics and baseline characteristics
Table 2. —Most common treatment-emergent adverse events reported by ≥5.0% of patients in any treatment group
Table 3. —Most common treatment-related adverse events reported by ≥2.0% of patients in any treatment group
Figure 2. —Mean plasma cortisol 24-hour AUC at baseline, week 26, and week 52. Patients who had both 0- and 24-hour measurements were included in the analysis. AUC, area under the curve; FP/S, fluticasone propionate/salmeterol; MF/F, mometasone furoate/formoterol.
*p≤ .043 versus baseline within treatment groups.
![Figure 2. —Mean plasma cortisol 24-hour AUC at baseline, week 26, and week 52. Patients who had both 0- and 24-hour measurements were included in the analysis. AUC, area under the curve; FP/S, fluticasone propionate/salmeterol; MF/F, mometasone furoate/formoterol.*p≤ .043 versus baseline within treatment groups.](/cms/asset/1f0b17b4-e00a-48de-bb6d-2f78a6b35924/ijas_a_514634_f0002_b.gif)
Figure 3. —Improvement in mean 24-hour total asthma symptom scores. Total asthma symptom scores are the sum of wheezing, coughing, and difficulty breathing scores, based on a scale of 0 (none) to 3 (severe). FP/S, fluticasone propionate/salmeterol; MF/F, mometasone furoate/formoterol.
![Figure 3. —Improvement in mean 24-hour total asthma symptom scores. Total asthma symptom scores are the sum of wheezing, coughing, and difficulty breathing scores, based on a scale of 0 (none) to 3 (severe). FP/S, fluticasone propionate/salmeterol; MF/F, mometasone furoate/formoterol.](/cms/asset/1825348b-1e94-422e-8b78-087040b5e7fe/ijas_a_514634_f0003_b.gif)